Recently Featured

Radiopharmaceutical Specialist Aktis Seeks an IPO

January 27, 2026
Aktis, a rising player in the radiopharmaceutical sector, has announced its intention to pursue an initial public offering (IPO). This strategic move comes at a time when the biotechnology market is showing signs of recovery, with increased optimism among investors regarding the potential for IPOs to rebound in the upcoming year. The timing of Aktis’s…

Boehringer Ingelheim Partners with Rectify to Develop Oral Medications for Chronic Kidney Disease

January 27, 2026
Boehringer Ingelheim has entered into a strategic partnership with Boston-based startup Rectify to develop oral medications targeting chronic kidney disease, a collaboration valued at up to $448 million in biobucks. This significant investment underscores Boehringer’s commitment to addressing unmet needs in renal therapeutics, particularly as the prevalence of chronic kidney disease continues to rise globally.…

AstraZeneca Invests $100 Million Upfront in Jacobio’s Pan-KRAS Inhibitor

January 26, 2026
AstraZeneca is committing $100 million upfront to acquire ex-China rights for Jacobio Pharma’s early-stage cancer drug, JAB-23E73, a pan-KRAS inhibitor. This strategic investment is part of a broader deal that could total up to $2 billion, contingent on the drug’s development milestones and commercial success. This collaboration underscores AstraZeneca’s focus on expanding its oncology portfolio,…

CMMI Proposes New Models to Lower Drug Prices to International Rates for Medicare Parts B, D

January 26, 2026
The Centers for Medicare & Medicaid Services’ (CMS) Innovation Center has unveiled two new drug pricing models aimed at aligning Medicare Parts B and D prices with international rates. These proposed models are designed to implement rebates based on international drug prices, which are often significantly lower than those currently faced by U.S. consumers. This…

Ongoing Cases